JP2013518905A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518905A5 JP2013518905A5 JP2012552126A JP2012552126A JP2013518905A5 JP 2013518905 A5 JP2013518905 A5 JP 2013518905A5 JP 2012552126 A JP2012552126 A JP 2012552126A JP 2012552126 A JP2012552126 A JP 2012552126A JP 2013518905 A5 JP2013518905 A5 JP 2013518905A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- composition
- seq
- chlorotoxin polypeptide
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710164760 Chlorotoxin Proteins 0.000 claims description 65
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 claims description 65
- 229960005534 chlorotoxin Drugs 0.000 claims description 65
- 229920001184 polypeptide Polymers 0.000 claims description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 239000004472 Lysine Substances 0.000 claims description 28
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 25
- 239000002246 antineoplastic agent Substances 0.000 claims description 22
- 150000001413 amino acids Chemical group 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 230000033115 angiogenesis Effects 0.000 claims description 6
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229940123237 Taxane Drugs 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010059866 Drug resistance Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000002280 anti-androgenic effect Effects 0.000 claims description 2
- 230000003388 anti-hormonal effect Effects 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 239000000051 antiandrogen Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000003886 aromatase inhibitor Substances 0.000 claims description 2
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 2
- 210000001130 astrocyte Anatomy 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 230000006800 cellular catabolic process Effects 0.000 claims description 2
- 230000001886 ciliary effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000000367 immunologic factor Substances 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 238000009830 intercalation Methods 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 208000030173 low grade glioma Diseases 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 208000021039 metastatic melanoma Diseases 0.000 claims description 2
- 230000000394 mitotic effect Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002575 ocular melanoma Diseases 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 239000000649 purine antagonist Substances 0.000 claims description 2
- 239000003790 pyrimidine antagonist Substances 0.000 claims description 2
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 201000003708 skin melanoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 231100000617 superantigen Toxicity 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 19
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30161510P | 2010-02-04 | 2010-02-04 | |
| US61/301,615 | 2010-02-04 | ||
| PCT/US2011/023823 WO2011097533A1 (en) | 2010-02-04 | 2011-02-04 | Chlorotoxin polypeptides and conjugates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015164731A Division JP6027200B2 (ja) | 2010-02-04 | 2015-08-24 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518905A JP2013518905A (ja) | 2013-05-23 |
| JP2013518905A5 true JP2013518905A5 (https=) | 2014-03-27 |
| JP5858932B2 JP5858932B2 (ja) | 2016-02-10 |
Family
ID=44355816
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552126A Active JP5858932B2 (ja) | 2010-02-04 | 2011-02-04 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| JP2015164731A Active JP6027200B2 (ja) | 2010-02-04 | 2015-08-24 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| JP2016201676A Active JP6181265B2 (ja) | 2010-02-04 | 2016-10-13 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015164731A Active JP6027200B2 (ja) | 2010-02-04 | 2015-08-24 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| JP2016201676A Active JP6181265B2 (ja) | 2010-02-04 | 2016-10-13 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9018347B2 (https=) |
| EP (2) | EP2531206B1 (https=) |
| JP (3) | JP5858932B2 (https=) |
| KR (1) | KR101923235B1 (https=) |
| CN (2) | CN106995493B (https=) |
| AU (1) | AU2011213678B2 (https=) |
| CA (1) | CA2788824C (https=) |
| CY (1) | CY1119276T1 (https=) |
| DK (1) | DK2531206T3 (https=) |
| ES (1) | ES2638871T3 (https=) |
| HR (1) | HRP20171291T1 (https=) |
| HU (1) | HUE034119T2 (https=) |
| IL (1) | IL221278B (https=) |
| LT (1) | LT2531206T (https=) |
| PL (1) | PL2531206T3 (https=) |
| PT (1) | PT2531206T (https=) |
| RS (1) | RS56231B1 (https=) |
| SI (1) | SI2531206T1 (https=) |
| SM (1) | SMT201700418T1 (https=) |
| WO (1) | WO2011097533A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE502048T1 (de) | 2005-04-22 | 2011-04-15 | Univ Washington | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
| US8227439B2 (en) | 2008-05-15 | 2012-07-24 | Morphotek, Inc. | Treatment of metastatic tumors |
| JP5858932B2 (ja) * | 2010-02-04 | 2016-02-10 | モルフォテック， インコーポレイテッド | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| JP2013532126A (ja) * | 2010-05-11 | 2013-08-15 | フレッド ハッチンソン キャンサー リサーチ センター | クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法 |
| AU2013204119B2 (en) * | 2010-05-11 | 2016-03-31 | Fred Hutchinson Cancer Center | Chlorotoxin variants, conjugates, and methods for their use |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| CN105008393A (zh) | 2012-12-10 | 2015-10-28 | 弗莱德哈钦森癌症研究中心 | 用于筛选的方法 |
| US9784730B2 (en) | 2013-03-21 | 2017-10-10 | University Of Washington Through Its Center For Commercialization | Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine |
| EP3046572B1 (en) | 2013-09-17 | 2025-07-30 | Blaze Bioscience, Inc. | Chlorotoxin conjugates and methods of use thereof |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| CN105801706B (zh) * | 2014-12-31 | 2019-10-22 | 深圳先进技术研究院 | 蝎氯毒素多肽-铁蛋白重链融合蛋白、自组装蛋白质纳米笼及其制备方法和应用 |
| CN104877016A (zh) * | 2015-04-30 | 2015-09-02 | 温州生物材料与工程研究所 | 折叠氯代毒素、氯代毒素变异体与折叠氯代毒素变异体及其制备工艺 |
| WO2016210376A2 (en) * | 2015-06-26 | 2016-12-29 | Fred Hutchinson Cancer Research Center | Therapeutic peptides and methods of use thereof |
| US11090358B2 (en) | 2015-09-09 | 2021-08-17 | Fred Hutchinson Cancer Research Center | Cartilage-homing peptides |
| CA3001833A1 (en) | 2015-10-13 | 2017-04-20 | City Of Hope | Chimeric antigen receptors containing a chlorotoxin domain |
| WO2017136769A1 (en) | 2016-02-04 | 2017-08-10 | Eisai R&D Management Co., Ltd. | Peptide drug conjugates |
| WO2017181149A1 (en) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| EP3442555A4 (en) * | 2016-04-15 | 2020-04-01 | Blaze Bioscience, Inc. | METHOD FOR TREATING BREAST CANCER |
| KR101678393B1 (ko) | 2016-08-25 | 2016-12-06 | (주)넥스젠바이오텍 | 피부 세포 증식 효과가 증가한 전갈독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선, 피부 탄력 증대 및 항노화 화장료 조성물 |
| KR102618373B1 (ko) * | 2016-12-09 | 2023-12-29 | 유에이비 리서치 파운데이션 | 키메라성 클로로톡신 수용체 |
| AU2018210157B2 (en) | 2017-01-18 | 2022-10-06 | Fred Hutchinson Cancer Center | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
| EP3595699A4 (en) | 2017-03-16 | 2020-12-23 | Blaze Bioscience, Inc. | PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE |
| AU2018283161A1 (en) | 2017-06-15 | 2020-01-02 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
| EP3681540A4 (en) | 2017-09-15 | 2021-05-19 | Eisai, Inc. | CHLOROTOXIN AGENT AND USES THEREOF |
| EP3727146A4 (en) | 2017-12-19 | 2021-10-06 | Blaze Bioscience, Inc. | TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE |
| US20220233694A1 (en) * | 2019-05-31 | 2022-07-28 | The Cleveland Clinic Foundation | Functionalized fullerene gel tumor treatment |
| EP4271702B1 (en) * | 2020-12-30 | 2024-11-06 | VRG Therapeutics Zrt. | Chlorotoxin derivatives and use thereof |
| CN113092609B (zh) * | 2021-03-31 | 2022-03-29 | 中国海洋大学 | 一种Gymnodimine毒素标准物质的制备方法 |
| CN113527416A (zh) * | 2021-08-11 | 2021-10-22 | 南开大学 | 一种硝基还原酶响应氨基酸及肿瘤乏氧荧光探针的制备方法 |
| KR20240015034A (ko) * | 2022-07-25 | 2024-02-02 | 충남대학교산학협력단 | Stichodactyla 독소 분비를 위한 재조합 발현 벡터및 이로 형질전환된 약독화 살모넬라 균주 |
| CN118767156B (zh) * | 2023-04-10 | 2025-11-21 | 湖南中晟全肽生物科技股份有限公司 | 一种氯毒素类似物的多肽偶联物及其用途 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| DE3407582A1 (de) | 1984-03-01 | 1985-09-05 | Dornier System Gmbh, 7990 Friedrichshafen | Schaltungsanordnung fuer einen regelkreis |
| EP0282581A4 (en) | 1986-09-19 | 1988-11-02 | Scripps Clinic Res | Monoclonal paratopic molecule directed to human ganglioside gd2. |
| US5171749A (en) | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
| US5591829A (en) | 1987-05-29 | 1997-01-07 | Matsushita; Shuzo | Antibodies modified with toxic substance |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5051364A (en) | 1989-02-16 | 1991-09-24 | The Salk Institute For Biological Studies | Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies |
| DE3909799A1 (de) | 1989-03-24 | 1990-09-27 | Behringwerke Ag | Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung |
| US5173504A (en) | 1989-04-21 | 1992-12-22 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5171741A (en) | 1989-04-21 | 1992-12-15 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5308608A (en) | 1989-06-07 | 1994-05-03 | University Of British Columbia | Photosensitizing Diels-Alder porphyrin derivatives |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| US5223253A (en) | 1989-09-28 | 1993-06-29 | American Home Products Corporation | Bovine vaccine compositions and method for preventing trichomonas infections using same |
| GB2250993B (en) | 1990-11-21 | 1995-02-15 | Inst Nat Sante Rech Med | Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| MX9205293A (es) | 1991-09-20 | 1993-05-01 | Syntex Sinergen Neuroscience J | Factores neurotrofico derivado del glial |
| US5314992A (en) | 1991-11-25 | 1994-05-24 | Trustees Of Dartmouth College | Lipocortin-1 receptor protein and its uses |
| EP0642353A1 (en) | 1992-05-14 | 1995-03-15 | Oncologix, Inc. | Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors |
| US5726304A (en) | 1992-10-30 | 1998-03-10 | The University Of British Columbia | Porphocyanine and CNC-expanded porphyrins |
| US5405957A (en) | 1992-10-30 | 1995-04-11 | The University Of British Columbia | Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use |
| UA29466C2 (uk) | 1993-01-14 | 2000-11-15 | Канзер Рісерч Кампейн Технолоджі, Лтд | Фармацевтична композиція з антипухлинною активністю |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5688773A (en) | 1994-08-17 | 1997-11-18 | The General Hospital Corporation | Method of selectively destroying neoplastic cells |
| US5648485A (en) | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
| US5985822A (en) | 1994-12-09 | 1999-11-16 | The Scripps Research Institute | Inhibition of glial cell proliferation with N-CAM homophilic peptides |
| US5756340A (en) | 1995-05-08 | 1998-05-26 | The Regents Of The University Of California | Insect control with multiple toxins |
| JP3809502B2 (ja) | 1995-05-30 | 2006-08-16 | 二郎 有川 | ハンタウィルス抗原蛋白質およびモノクローナル抗体 |
| JPH0971559A (ja) | 1995-06-29 | 1997-03-18 | Nippon Nohyaku Co Ltd | ヒドロキシルアミン誘導体及び該化合物を含有する殺菌剤 |
| JPH0971599A (ja) | 1995-09-06 | 1997-03-18 | Nippon Seibutsu Kagaku Kenkyusho | 鶏貧血ウイルス（ｃａｖ）感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン |
| US6667156B2 (en) * | 1995-12-27 | 2003-12-23 | Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
| US5905027A (en) | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
| US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
| DK0983273T3 (da) | 1997-05-07 | 2002-04-22 | Univ British Columbia | Ethylenglycolestere af monohydrobenzoporphyrinderivater som fotoaktive midler |
| US5880145A (en) | 1997-05-07 | 1999-03-09 | The University Of British Columbia | Class of benzoporphyrin derivative photoactive compounds |
| US6130101A (en) | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
| AU748250B2 (en) | 1997-12-05 | 2002-05-30 | Kyogo Itoh | Tumor antigen peptide derivatives |
| AU5197599A (en) | 1998-08-12 | 2000-03-06 | Daiichi Pure Chemicals Co., Ltd. | Fluorescent labelling reagents |
| US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6767635B1 (en) | 1999-09-14 | 2004-07-27 | Biomedical Apherese Systeme Gmbh | Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
| US6623936B1 (en) | 1999-09-24 | 2003-09-23 | Imgenex | Compositions and methods for improved detection and classification of neoplasms |
| AU4305101A (en) | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
| DE10020376A1 (de) | 2000-04-26 | 2001-11-08 | Inst Zelltechnologie E V | Dynamische Marker |
| CA2427858A1 (en) | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| WO2002069896A2 (en) | 2001-03-01 | 2002-09-12 | Northwest Hospital | Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation |
| WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| WO2003000203A2 (en) | 2001-06-26 | 2003-01-03 | Uab Research Foundation | Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling |
| CA2453603C (en) | 2001-07-16 | 2007-01-02 | Maytag Corporation | Method and system for refrigerator with integrated presentation mode |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US6972326B2 (en) | 2001-12-03 | 2005-12-06 | Molecular Probes, Inc. | Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes |
| WO2003066663A2 (en) | 2002-02-04 | 2003-08-14 | Auburn University | Peptides for recognition and targeting of glial cell tumors |
| US20030232013A1 (en) | 2002-02-22 | 2003-12-18 | Gary Sieckman | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
| WO2003101474A1 (en) | 2002-05-31 | 2003-12-11 | Transmolecular, Inc. | Combination chemotherapy with chlorotoxin |
| US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
| US7560160B2 (en) | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
| US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
| EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| DE10328251A1 (de) | 2003-06-24 | 2005-01-13 | Toximed Gmbh | Pharmazeutischer Wirkstoff |
| WO2005053611A2 (en) | 2003-11-26 | 2005-06-16 | Transmolecular, Inc. | Treatment of phosphatidylinositol phospholipid disorders |
| US20080153746A1 (en) | 2004-04-06 | 2008-06-26 | Transmolecular, Inc. | Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers |
| DE602005019728D1 (de) | 2004-04-06 | 2010-04-15 | Transmolecular Inc | Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat |
| CA2565701A1 (en) | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| JP2008507280A (ja) | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
| GB0422901D0 (en) | 2004-10-14 | 2004-11-17 | Ares Trading Sa | Lipocalin protein |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
| US20070037232A1 (en) | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
| EP1871911A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
| WO2006110582A1 (en) | 2005-04-08 | 2006-10-19 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| ATE502048T1 (de) | 2005-04-22 | 2011-04-15 | Univ Washington | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
| CN101232903A (zh) * | 2005-04-22 | 2008-07-30 | 安姆根有限公司 | 具有延长的血液半衰期的毒素肽 |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| MX2008002149A (es) | 2005-08-18 | 2008-04-22 | Ambrx Inc | Composiciones de arnt y sus usos. |
| US20070084929A1 (en) | 2005-10-17 | 2007-04-19 | Hitoshi Watanabe | Barcode reader with a music player |
| EP2147927A3 (en) | 2006-03-31 | 2010-09-01 | Transmolecular, Inc. | Use of 131i-tm-601 for the diagnosis and treatment of gliomas |
| EP2029157A4 (en) | 2006-05-19 | 2009-11-18 | Georgia Tech Res Inst | ABC TRANSPORTERLIGAND |
| CN101003788A (zh) | 2006-09-21 | 2007-07-25 | 武汉大学 | 一种蝎抗肿瘤转移肽及其制备方法和应用 |
| CN100564517C (zh) | 2006-09-21 | 2009-12-02 | 武汉大学 | 一种蝎抗神经胶质瘤肽及其制备方法和应用 |
| PE20081140A1 (es) * | 2006-10-25 | 2008-09-22 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| US20090004105A1 (en) * | 2007-06-27 | 2009-01-01 | Zhen Cheng | Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin |
| CA2696303A1 (en) | 2007-08-07 | 2009-02-12 | Transmolecular, Inc. | Chlorotoxins as drug carriers |
| US20110283260A1 (en) | 2007-08-31 | 2011-11-17 | Iosemantics, Llc | Quality assurance tools for use with source code and a semantic model |
| EP2211913A4 (en) | 2007-10-12 | 2010-12-22 | Transmolecular Inc | SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS |
| US7904868B2 (en) | 2007-10-17 | 2011-03-08 | International Business Machines Corporation | Structures including means for lateral current carrying capability improvement in semiconductor devices |
| US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
| US20090124022A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
| US20090269777A1 (en) | 2007-10-19 | 2009-10-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US20090123970A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| CA2702611A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US20090176274A1 (en) | 2007-10-19 | 2009-07-09 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| US20090123946A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| CN101910845A (zh) | 2007-11-15 | 2010-12-08 | 比奥波托诊断股份公司 | 个体分子形式的生物标志的诊断用途 |
| ES2658852T3 (es) | 2008-01-18 | 2018-03-12 | Visen Medical, Inc. | Agentes de imaginología fluorescentes |
| US9308239B2 (en) | 2008-02-26 | 2016-04-12 | The Penn State Research Foundation | Methods and compositions for treatment of retinoid-responsive conditions |
| US8093060B2 (en) | 2008-02-28 | 2012-01-10 | Canon Kabushiki Kaisha | Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same |
| CN102026671B (zh) | 2008-03-14 | 2014-09-03 | Visen医药公司 | 整联蛋白靶向试剂及使用其的体内和体外成像方法 |
| CN102056617A (zh) | 2008-03-20 | 2011-05-11 | 特兰斯莫莱库拉公司 | 血管生成的抑制 |
| GB0807831D0 (en) | 2008-04-29 | 2008-06-04 | Cambridge Entpr Ltd | Agents for imaging cell death |
| CN101270158B (zh) | 2008-04-30 | 2010-12-22 | 武汉大学 | 一种靶向抗神经胶质瘤蛋白及制备方法和用途 |
| US8227439B2 (en) | 2008-05-15 | 2012-07-24 | Morphotek, Inc. | Treatment of metastatic tumors |
| JP2009300110A (ja) | 2008-06-10 | 2009-12-24 | Olympus Corp | 移植細胞の光学的検出方法又はイメージング方法 |
| JP5711118B2 (ja) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン |
| JP5744723B2 (ja) | 2008-09-12 | 2015-07-08 | 日東電工株式会社 | 線維性疾患のイメージング剤 |
| US20100098637A1 (en) | 2008-09-23 | 2010-04-22 | The Regents Of The University Of Michigan | Dye-loaded nanoparticle |
| CN101381405B (zh) | 2008-09-24 | 2011-07-27 | 武汉摩尔生物科技有限公司 | 基因工程肿瘤靶向kct-w1多肽及制备方法和用途 |
| JP2010085108A (ja) | 2008-09-29 | 2010-04-15 | Nano Factory:Kk | 生体光イメージング用プローブ |
| US20100105150A1 (en) | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
| CN102791827B (zh) | 2009-11-09 | 2016-11-16 | 华盛顿大学商业化中心 | 官能化发色聚合物点及其生物共轭体 |
| CN101921769B (zh) | 2010-01-11 | 2012-07-25 | 山西大学 | 一种重组腺病毒及其制备方法和应用 |
| WO2011094671A2 (en) | 2010-01-29 | 2011-08-04 | The Uab Research Foundation | N-terminally conjugated polypeptides for targeted therapy and diagnosis |
| JP5858932B2 (ja) * | 2010-02-04 | 2016-02-10 | モルフォテック， インコーポレイテッド | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| CN101824084A (zh) | 2010-04-08 | 2010-09-08 | 山西大学 | 靶向性抗胶质瘤蛋白质及其应用 |
| JP2013532126A (ja) * | 2010-05-11 | 2013-08-15 | フレッド ハッチンソン キャンサー リサーチ センター | クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法 |
| NZ606584A (en) | 2010-08-16 | 2014-10-31 | Pieris Ag | Binding proteins for hepcidin |
| CN104877016A (zh) * | 2015-04-30 | 2015-09-02 | 温州生物材料与工程研究所 | 折叠氯代毒素、氯代毒素变异体与折叠氯代毒素变异体及其制备工艺 |
-
2011
- 2011-02-04 JP JP2012552126A patent/JP5858932B2/ja active Active
- 2011-02-04 US US13/577,169 patent/US9018347B2/en active Active
- 2011-02-04 EP EP11740464.0A patent/EP2531206B1/en active Active
- 2011-02-04 CA CA2788824A patent/CA2788824C/en active Active
- 2011-02-04 RS RS20170847A patent/RS56231B1/sr unknown
- 2011-02-04 KR KR1020127023002A patent/KR101923235B1/ko active Active
- 2011-02-04 PL PL11740464T patent/PL2531206T3/pl unknown
- 2011-02-04 AU AU2011213678A patent/AU2011213678B2/en active Active
- 2011-02-04 HU HUE11740464A patent/HUE034119T2/en unknown
- 2011-02-04 WO PCT/US2011/023823 patent/WO2011097533A1/en not_active Ceased
- 2011-02-04 HR HRP20171291TT patent/HRP20171291T1/hr unknown
- 2011-02-04 DK DK11740464.0T patent/DK2531206T3/en active
- 2011-02-04 PT PT117404640T patent/PT2531206T/pt unknown
- 2011-02-04 LT LTEP11740464.0T patent/LT2531206T/lt unknown
- 2011-02-04 ES ES11740464.0T patent/ES2638871T3/es active Active
- 2011-02-04 SM SM20170418T patent/SMT201700418T1/it unknown
- 2011-02-04 CN CN201610856180.2A patent/CN106995493B/zh active Active
- 2011-02-04 SI SI201131279T patent/SI2531206T1/sl unknown
- 2011-02-04 EP EP17173578.0A patent/EP3238735A1/en active Pending
- 2011-02-04 CN CN201180012427.8A patent/CN102844044B/zh active Active
-
2012
- 2012-08-02 IL IL221278A patent/IL221278B/en active IP Right Grant
-
2014
- 2014-08-01 US US14/450,182 patent/US9234015B2/en active Active
-
2015
- 2015-08-24 JP JP2015164731A patent/JP6027200B2/ja active Active
- 2015-12-01 US US14/956,261 patent/US9637526B2/en active Active
-
2016
- 2016-10-13 JP JP2016201676A patent/JP6181265B2/ja active Active
-
2017
- 2017-03-23 US US15/468,085 patent/US10183975B2/en active Active
- 2017-08-30 CY CY20171100911T patent/CY1119276T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518905A5 (https=) | ||
| ES2638871T3 (es) | Polipéptidos clorotoxina y conjugados y usos de los mismos | |
| CN113453720B (zh) | 双配体药物偶联体及其用途 | |
| AU2018250312C1 (en) | Bioorthogonal compositions | |
| JP6968921B2 (ja) | 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション | |
| US12296018B2 (en) | Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same | |
| US10111963B2 (en) | Nanoparticle drug conjugates | |
| US11518996B2 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
| Ayalew et al. | Conjugation of paclitaxel to hybrid peptide carrier and biological evaluation in jurkat and A549 cancer cell lines | |
| JP2011520914A5 (https=) | ||
| JP2010535811A5 (https=) | ||
| CN102625839A (zh) | Sparc反义组合物和其用途 | |
| Rusiecka et al. | Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs | |
| CN111447941A (zh) | 用于细胞内递送装订肽的多肽缀合物 | |
| CN111093718A (zh) | 治疗性纳米缀合物及其用途 | |
| US20260076991A1 (en) | Hyaluronic Acid Nanoparticles Comprising NADPH Oxidases Inhibitors and Uses in Treating Cancer | |
| JP2026510850A (ja) | リンカー及びそれを使用したカップリング薬物、抗体薬物複合体並びにその応用 | |
| CN103108641A (zh) | Sdf-1结合性核酸及其在癌症治疗中的用途 | |
| Debnath et al. | Peptide-drug conjugates in targeted drug delivery to cancer | |
| KR20130136862A (ko) | 생체고분자 및 중합된 핵산 복합체를 포함하는 핵산 전달체 | |
| Wang et al. | Peptide modified lipid nanoparticles Co-Delivering IL-12 mRNA and PD-L1 siRNA for glioblastoma immunotherapy | |
| CN117836316A (zh) | 能够抑制myc驱动的转录的共价蛋白质二聚体的合成 | |
| HK40052006A (en) | Bi-ligand drug conjugate and use thereof | |
| Splith et al. | Cellular delivery and biological activity of metall complex-peptide conjugates | |
| HK1240244B (zh) | 氯毒素多肽和结合物及其应用 |